PTCHF — PureTech Health plc
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1782999 ·
Last close
$1.70
Market Cap
$413.81M
52W High
$1.92
52W Low
$1.55
ADV30
5,803
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Dec 2025 | — | — | — | — | 534,710,000 | 252,470,000 | 229,034,000 |
| Jun 2025 | — | — | — | — | 553,242,000 | 260,604,000 | 184,217,000 |
| Dec 2024 | — | — | — | — | 602,635,000 | 280,641,000 | 194,702,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-77,231,000
Inventory
—
Receivables
—
ST Investments
$24,829,000
EBIT TTM
—
Pretax Income TTM
—
Interest Exp TTM
—
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,659,000
EBITDA
$-96,830,000
Free Cash Flow
$-89,990,376
Enterprise Value
$321,953,920
Total Cash
$288,716,000
Total Debt
$203,256,000
Shares Out
243,418,190
Trailing EPS
$-0.46
Book Value
$1.29
ROE
-30.9%
ROA
-10.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,659,000 | -98,525,000 | -109,739,000 | 534,710,000 | 229,034,000 | — | -85,131,000 |
| Dec 2024 | 4,315,000 | -136,095,000 | 53,510,000 | 602,635,000 | 194,702,000 | — | -134,369,000 |
| Dec 2023 | 750,000 | -146,201,000 | -65,697,000 | 693,973,000 | 235,742,000 | — | -105,917,000 |
| Dec 2022 | 2,090,000 | -197,806,000 | -50,354,000 | 702,647,000 | 155,058,000 | — | -178,792,000 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INDP | Indaptus Therapeutics, Inc. | $405.41M | $3.58 | — |
| MNPR | Monopar Therapeutics | $400.40M | $59.77 | — |
| KMDA | KAMADA LTD | $429.18M | $7.44 | — |
| OVID | Ovid Therapeutics Inc. | $429.27M | $2.30 | — |
| EBS | Emergent BioSolutions Inc. | $429.28M | $8.32 | — |
News headlines (Yahoo Finance, 1h cache)
PureTech Health: Results of Annual General Meeting
2026-06-10 17:14 · Yahoo
PureTech Founded Entity Seaport Therapeutics Reports Positive Multiple-Ascending Dose Data from Phase 1 Proof-of-Concept Trial of GlyphAgo™ in Healthy Volunteers
2026-06-09 06:00 · Yahoo
PureTech to Showcase Deupirfenidone Program at the American Thoracic Society International Conference
2026-05-13 11:00 · Yahoo
Seaport Therapeutics stock pops 17% on Nasdaq debut
2026-05-01 17:32 · Yahoo
PureTech Health shares boosted as investee Seaport Therapeutics prices Nasdaq IPO
2026-05-01 08:26 · Yahoo
PureTech Health H2 Earnings Call Highlights
2026-04-29 20:30 · Yahoo
PureTech Announces Annual Results for Year Ended December 31, 2025
2026-04-29 06:01 · Yahoo
PureTech Announces Intention to Voluntarily Delist American Depositary Shares from Nasdaq and Concentrate Trading on the London Stock Exchange
2026-04-29 06:00 · Yahoo
PureTech Founded Entity Seaport Therapeutics Adds Intra-Cellular Therapies Founder and CEO, Dr. Sharon Mates, to its Board of Directors
2026-04-27 11:05 · Yahoo
PureTech Reports Positive Topline Data from Phase 1b Trial of LYT-200 in Relapsed/Refractory (R/R) High-Risk (HR) Myelodysplastic Syndrome (MDS) and R/R Acute Myeloid Leukemia (AML)
2026-04-22 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.